

Ulcerative Colitis

Ulcerative colitis (UC) is a chronic, immune-mediated disease of the large intestine that causes continuous mucosal inflammation extending variably from the rectum to the more proximal colon.^{1,2} UC is an unpredictable disease with varying patterns of inflammatory activity changing over time.³ UC belongs to a group of diseases called inflammatory bowel disease (IBD).^{2,4}



At least 6.8 million people worldwide live with IBD.⁵



UC is frequently diagnosed before the age of 30, but **can occur at any age.**^{2,4}



In a given year, **52 percent of people** with UC have active symptoms.²



5-20 percent of people with IBD have a first-degree relative with IBD.^{2,4}



23 to 45 percent of people with UC will eventually require surgery.⁶

The Signs and Symptoms of Ulcerative Colitis⁴

Bloody stool

Diarrhea

Abdominal pain and cramping

Rectal pain and bleeding



Urgency to defecate

Inability to defecate despite urgency

Fatigue

Fever

Unpredictability of symptoms is a key burden in UC, with patients commonly experiencing a loss of bodily function control.⁷

abbvie

ALL-IMMG-210100
July 2022

The Impact is Beyond Physical



Symptoms such as **bowel urgency and incontinence and uncertainty about disease relapses** lead to substantial burden and disability among patients, which is often underestimated.^{8,9}

Over two thirds of IBD patients consider toilet availability when planning to attend an event.⁹



Managing UC and Establishing Treatment Goals

Because symptoms of UC can be unpredictable and early diagnosis and regular monitoring can lead to better outcomes, it is important that patients assess symptoms routinely and speak with their doctors to share how the disease impacts their daily lives.¹⁰

Significant unmet needs remain for people living with UC.¹¹ Early diagnosis and disease management are important to help control inflammation and improve long-term outcomes.¹⁰ Persistent inflammation and more severe disease can cause further bowel damage.¹²

Treatment goals are evolving beyond symptom management to include clinical remission and mucosal healing, improving quality of life without the need for surgery and absence of disability.^{2,13,14}

1. Gajendran M, et al. A comprehensive review and update on ulcerative colitis. *Dis-Mon DM*. 2019;65(12):100851. doi:10.1016/j.disamonth.2019.02.004 2. Crohn's & Colitis Foundation of America. The Facts about Inflammatory Bowel Diseases. Crohn's & Colitis Foundation. Published November 2014. Accessed August 13, 2021. <https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf> 3. Monstad I, et al. Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies. *Ann Gastroenterol*. 2014;27(2):95-104. 4. Mayo Clinic. Ulcerative colitis. Symptoms and Causes. Mayo Clinic. Published 2020. Accessed August 13, 2021. <https://www.mayoclinic.org/diseases-conditions/ulcerative-colitis/symptoms-causes/syc-20353326> 5. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol*. 2020 Jan;5(1):17-30. doi: 10.1016/S2468-1253(19)30333-4. Epub 2019 Oct 21. 6. Crohn's and Colitis Foundation of America. Surgery for Crohn's Disease and Ulcerative Colitis. Available at: https://www.crohnscolitisfoundation.org/sites/default/files/legacy/assets/pdfs/surgery_brochure_final.pdf. 7. Rapport F, Clement C, Seagrove AC, Alrubaiy L, Hutchings HA, Williams JG. Patient views about the impact of ulcerative colitis and its management with drug treatment and surgery: a nested qualitative study within the CONSTRUCT trial. *BMC Gastroenterol*. 2019;19(1):166. 8. Mehta F. Report: economic implications of inflammatory bowel disease and its management. *Am J Manag Care*. 2016;22(3 Suppl):s51-60. 9. Lönnfors S, et al. IBD and health-related quality of life – discovering the true impact. *J Crohns Colitis*. 2014;8(10):1281-1286. doi:10.1016/j.crohns.2014.03.005. 10. Wylezinski LS, et al. Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes. *J Clin Med*. 2019 Apr 11;8(4):493. doi: 10.3390/jcm8040493. 11. Danese S, et al. Unmet medical needs in Ulcerative Colitis: An Expert Group Consensus. *Dig Dis*. 2019;37(4):266-283. doi:10.1159/000496739 12. Axelrad JE, et al. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. *World J Gastroenterol*. 2016 May 28; 22(20): 4794-4801. Published online 2016 May 28. doi: 10.3748/wjg.v22.i20.4794. 13. Van Assche G, et al. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study. *Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver*. 2016;48(6):592-600. doi:10.1016/j.jld.2016.01.011. 14. Dave M and Loftus EV. Mucosal Healing in Inflammatory Bowel Disease—A True Paradigm of Success? *Gastroenterol Hepatol (N Y)*. 2012 Jan; 8(1): 29-38.